Literature DB >> 16244105

Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators.

Marco A Cassatella1, Veronica Huber, Federica Calzetti, Daniela Margotto, Nicola Tamassia, Giuseppe Peri, Alberto Mantovani, Licia Rivoltini, Cristina Tecchio.   

Abstract

Neutrophils are versatile cells, which play a role, not only in inflammatory processes but also in immune and antitumoral responses. Recently, we have reported that interferon (IFN)-activated neutrophils are able to release biologically active tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/APO2 ligand), a molecule exerting selective, apoptotic activities toward tumor and virus-infected cells, as well as immunoregulatory functions on activated T lymphocytes. Herein, we show that only a minor fraction of the total TRAIL, newly synthesized by IFN-activated neutrophils within 24 h, is released outside, the rest being retained intracellularly, mainly in secretory vesicles and light membrane fractions. We demonstrate that the intracellular pool of TRAIL present in IFN-pretreated neutrophils is rapidly mobilizable to the cell surface and can be secreted following exposure to proinflammatory mediators such as TNF-alpha, lipopolysaccharide, formyl-methionyl-leucyl-phenylalanine, CXC chemokine ligand 8/interleukin-8, insoluble immunocomplexes, and heat shock protein Gp96. These various proinflammatory agonists functioned as effective secretagogue molecules only, in that they failed to augment TRAIL mRNA expression or TRAIL de novo synthesis in freshly isolated neutrophils or cultured with or without IFN. In addition, supernatants from IFN-treated neutrophils stimulated with proinflammatory mediators induced the apoptosis of target cells more effectively than supernatants from neutrophils activated with IFNs alone. Collectively, our results uncover a novel mechanism, whereby the release of soluble TRAIL by neutrophils can be greatly amplified and further reinforce the notion that neutrophils are important cells in tumor surveillance and immunomodulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244105     DOI: 10.1189/jlb.0805431

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  28 in total

Review 1.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

Review 2.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

Review 3.  Mechanisms regulating neutrophil survival and cell death.

Authors:  María Laura Gabelloni; Analía Silvina Trevani; Juan Sabatté; Jorge Geffner
Journal:  Semin Immunopathol       Date:  2013-02-01       Impact factor: 9.623

4.  Circulating cell death biomarker TRAIL is associated with increased organ dysfunction in sepsis.

Authors:  Edward J Schenck; Kevin C Ma; David R Price; Thomas Nicholson; Clara Oromendia; Eliza Rose Gentzler; Elizabeth Sanchez; Rebecca M Baron; Laura E Fredenburgh; Jin-Won Huh; Ilias I Siempos; Augustine Mk Choi
Journal:  JCI Insight       Date:  2019-05-02

Review 5.  Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Authors:  Hope M Amm; Patsy G Oliver; Choo Hyung Lee; Yufeng Li; Donald J Buchsbaum
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

Review 6.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

Review 7.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 8.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

Review 9.  Role of neutrophils in BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; Michael A O'Donnell; Thomas S Griffith
Journal:  Urol Oncol       Date:  2008 Jul-Aug       Impact factor: 3.498

Review 10.  Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; William M Nauseef; Thomas S Griffith
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.